Search

Author/Creator Ferris, L.K.

1. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. (15th January 2020)

Authors:
Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.
Other Names:
Vender Ronald investigator.; Lomaga Mark A. investigator.; Delorme Isabelle investigator.; Hong Chih‐Ho investigator.; Langley Richard L. investigator.; Albrecht Lorne investigator.; Guenther Lyn investigator.; Maari Catherine investigator.; Papp Kim investigator.; Singh Ohson Kamal K. investigat...
Journal:
British journal of dermatology
Issue:
Volume 182:Number 6(2020)
Page Start:
1348
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. (1st June 2020)

Authors:
Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.; Vender, Ronald; Lomaga, Mark A.; Delorme, Isabelle
Journal:
British journal of dermatology
Issue:
Volume 182:Number 6(2020)
Page Start:
1348
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis. (1st June 2020)

Authors:
Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.
Journal:
British journal of dermatology
Issue:
Volume 182:Number 6(2020)
Page Start:
e193
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR). (16th November 2017)

Authors:
Blauvelt, A.; Ferris, L.K.; Yamauchi, P.S.; Qureshi, A.; Leonardi, C.L.; Farahi, K.; Fakharzadeh, S.; Hsu, M.‐C.; Li, S.; Chevrier, M.; Smith, K.; Goyal, K.; Chen, Y.; Muñoz‐Elías, E.J.; Callis Duffin, K.
Journal:
British journal of dermatology
Issue:
Volume 177:Number 6(2017)
Page Start:
1552
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR). (1st December 2017)

Authors:
Blauvelt, A.; Ferris, L.K.; Yamauchi, P.S.; Qureshi, A.; Leonardi, C.L.; Farahi, K.; Fakharzadeh, S.; Hsu, M.‐C.; Li, S.; Chevrier, M.; Smith, K.; Goyal, K.; Chen, Y.; Muñoz‐Elías, E.J.; Callis Duffin, K.
Journal:
British journal of dermatology
Issue:
Volume 177:Number 6(2017)
Page Start:
1552
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis. (17th March 2022)

Authors:
Gooderham, M.; Pinter, A.; Ferris, L.K.; Warren, R.B.; Zhan, T.; Zeng, J.; Soliman, A.M.; Kaufmann, C.; Kaplan, B.; Photowala, H.; Strober, B.
Journal:
Journal of the European Academy of Dermatology and Venereology
Issue:
Volume 36:Number 6(2022)
Page Start:
855
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗